The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. (2022) Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L, Mougiakakos D, et al. Journal article IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL (2021) Codo P, Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, et al. Conference contribution BNT211: A PHASE I/II TRIAL TO EVALUATE SAFETY AND EFFICACY OF CLDN6 CAR-T CELLS AND VACCINE-MEDIATED IN VIVO EXPANSION IN PATIENTS WITH CLDN6-POSITIVE ADVANCED SOLID TUMORS (2021) Mackensen A, Koenecke C, Haanen J, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, et al. Conference contribution TUMOR-DERIVED GDF-15 PREVENTS THERAPY SUCCESS OF CHECKPOINT INHIBITORS BY BLOCKING T-LYMPHOCYTE RECRUITMENT (2021) Haake M, Schaefer T, Haack B, Vashist N, Genssler S, Harter P, Martens A, et al. Conference contribution EARLY BLOOD CELL COUNT TEST (BCT) FOR SURVIVAL PREDICTION FOR NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ATEZOLIZUMAB: INTEGRATED ANALYSIS OF 4 MULTICENTER CLINICAL TRIALS (2021) Zhou JG, Wong AHH, Wang H, Jin SH, Tan F, Chen YZ, He SS, et al. Conference contribution IMMUNOMONITORING OF CD19. CAR T-CELLS IN LARGE B-CELL LYMPHOMA- A TWO-CENTER EXPERIENCE (2021) Blumenberg V, Völkl S, Busch G, Baumann S, Winkelmann M, Tast B, Nixdorf D, et al. Conference contribution DIVERSITY OF CD4(+) BLOOD T-CELL CLONALITY PREDICTS LONGER SURVIVAL WITH CTLA4 OR PD-1 CHECKPOINT INHIBITION IN ADVANCED MELANOMA (2021) Arakawa A, Vollmer S, Tietze J, Galinski A, Heppt M, Berking C, Prinz JC Conference contribution IN VIVO STUDIES OF IMMUNOMODULATORY A-CTLA-4 ANTIBODY IN A HUMANIZED MOUSE MODEL (2021) Reitinger C, Nimmerjahn F Conference contribution CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma (2021) Klümper N, Ralser DJ, Zarbl R, Schlack K, Schrader AJ, Rehlinghaus M, Hoffmann MJ, et al. Journal article Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: A case report (2021) Jitschin R, Kharboutli S, Stoll A, Büttner-Herold M, Schmidt D, Rösler W, Mackensen A, et al. Journal article